Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
Treatment With Intent to Generate Endovascular Reperfusion
NCT03474549 · View on ClinicalTrials.gov ↗
Study Summary
Tigertriever is a CE marked mechanical revascularization device indicated to restore blood flow by removing thrombus from a large intracranial vessel in patients experiencing ischemic stroke within 8 hours of symptom onset. Patients who are ineligible for IV t-PA or who fail IV t-PA therapy are candidates for treatment. The objective of the TIGER Study is to evaluate the safety and effectiveness of the Tigertriever device in restoring blood flow in the neurovasculature by removing thrombus in patients experiencing ischemic stroke due to a large vessel occlusion (LVO). This study is designed to support substantial equivalence to approved and marketed products such as the Solitaire or Trevo Retriever.
Conditions Studied
Interventions
- DEVICE Tigertriever revascularization device
Study Locations (17)
Florida
- Tenet Health — Coral Springs
- Baptist Health Research Institute — Jacksonville
- Baptist Health South Florida — Miami
- University of Miami — Miami
California
- UCLA medical center — Los Angeles
- Los Robles — Thousand Oaks
New York
- Maimonides Medical Center — Brooklyn
- University of Buffalo — Buffalo
Ohio
- Riverside Methodist Hospital — Columbus
- Mercy Health — Toledo
Georgia
- WellStar Research Institute — Marietta
Iowa
- University of Iowa — Iowa City
Massachusetts
- University of Massachusetts — Worcester
Oregon
- Oregon Health & Science University — Portland
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 160 participants |
| Start Date | 2018-05-09 |
| Est. Completion | 2020-06-30 |
| Phase | NA |
Interested in This Trial?
Always speak with your doctor before enrolling in a clinical trial.
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03474549
The ClinicalTrials.gov registry entry for NCT03474549 describes a study currently listed as completed. It is categorized as NA, which is the standard way researchers label where a study sits along the investigational pathway from early safety work through later efficacy and post-marketing evaluation. The registered enrollment target is 160 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Rapid Medical, which has 3 total studies on file at ClinicalTrials.gov, and sponsors are the parties responsible for study design, oversight, and regulatory filings.
The record links to 1 condition, with Ischemic Stroke appearing as the primary indexed condition, and to 1 intervention — of which Tigertriever revascularization device is the first listed. Interventions can include drugs, devices, procedures, behavioral programs, or observational arms, and each is tracked as a separate registry field so that downstream queries can filter accurately. When a trial lists multiple interventions, it usually reflects a multi-arm design or a comparison protocol rather than a single treatment being tested in isolation. The brief summary published in the registry is the clearest source of protocol intent and should be read before drawing conclusions from any sidebar tags.
Geographic footprint matters for practical reasons: NCT03474549 reports 17 study locations spanning 11 distinct geographic areas — top geographies include Florida, California, New York. A larger site network tends to correlate with broader recruitment capacity, but it does not imply anything about study quality, and site-level enrollment status can diverge from the overall registry status shown above. Every data point on this page comes from the public ClinicalTrials.gov dataset and is reproduced here for reference only; it is not a medical recommendation, an endorsement of the sponsor, or an invitation to enroll. Verify current status, eligibility criteria, and contact details directly at ClinicalTrials.gov, and discuss any participation decision with your own healthcare provider.
Frequently Asked Questions
What is clinical trial NCT03474549 about?
NCT03474549 is a clinical study titled "Treatment With Intent to Generate Endovascular Reperfusion". Tigertriever is a CE marked mechanical revascularization device indicated to restore blood flow by removing thrombus from a large intracranial vessel in patients experiencing ischemic stroke within 8 hours of symptom onset. Patients who are ineligible for IV t-PA or who fail IV t-PA therapy are cand...
What is the current status of trial NCT03474549?
This trial is currently completed. It is a NA study. The enrollment target is 160 participants. The study started on 2018-05-09. Estimated completion is 2020-06-30.
What conditions does trial NCT03474549 study?
This clinical trial studies the following conditions: Ischemic Stroke. These conditions were identified from the trial registry and reflect the primary focus areas of the research.
What interventions are being tested in trial NCT03474549?
The interventions under investigation include: Tigertriever revascularization device (DEVICE). Each intervention is being evaluated for safety and efficacy as part of this clinical study.
Who is sponsoring clinical trial NCT03474549?
This trial is sponsored by Rapid Medical, which has 3 total clinical trials registered on ClinicalTrials.gov. The sponsor is responsible for the study's design, funding, and regulatory compliance.
Where is trial NCT03474549 being conducted?
This trial has 17 study locations across California, Florida, Georgia, Iowa, Massachusetts. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
How Clinical Trials Work
Understand phases 1-4, trial design, randomization, and the informed consent process.
Patient Rights in Clinical Trials
Your rights as a participant: consent, withdrawal, privacy, and who to contact.
Finding the Right Clinical Trial
A practical guide to searching trials, understanding eligibility, and evaluating options.
All Guides
Browse our complete library of clinical trial educational resources.
Read our methodology — how this data is sourced, computed, and verified.